UNIVERSITY
Ankara University Faculty of Medicine
UNIVERSITY WHERE HE TAKES EXPERTISE
Göztepe Training and Research Hospital General Surgery
CONGRESSES ATTENDED
National Endoscopic Laparoscopic Surgery Congress
World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension
Bariatric and Metabolic Surgery Congress
Cerrahpaşa Surgery Meetings Turkish Bariatric Surgery Association
Mehr lesen
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Mehr lesen
Arztbesuch | preis auf anfrage |
Radiojodtherapie | $5000 - $7000 |
Strahlentherapie bei Hirntumoren | $4000 - $6000 |
Mastektomie | $5000 - $7500 |
Gastroenterology
Pendik Medipol University Hospital
1999 Karadeniz Technical University, Gastroenterology
1997Atatürk University, Internal Diseases Professorship
1992 Atatürk University, Internal Diseases Associated Professorship
1985 Atatürk University, Internal Diseases Specialist
1981 Atatürk University Faculty of Medicine
1- Nihat Okçu Gülçin Polat,Arif Yılmaz,Mehmet Koruk,The demographıc features of gastrıc cancers ın erzurum(Eurasian J Med 2000; 32: 63-65)
2- Üst Gastrointestinal Kanamalı Olguların Bir Değerlendirilmesi. Klinik Bilimler-Doktor.2000, - E.akarsu,N.Okçu, ve Ark.Kuzeydoğu Anadolu’da 6:4:435-438
3-N.Okçu, A.yılmaz. İ.kiki,M.D.onuk, C.gündoğdu, H.uzunismail. Tanısal Üst Gastrointestinal endoskopi Sonuçlarımız. Atatürk Üniversitesi Tıp Dergisi 1997,29 (2):486
4-N. Okçu, M.gündoğdu, M.D. onuk, İ.kiki, l.cerrahoğlu, k.yılmaz, i. çapoğlu. Nonsteroid Anti İnflamatuar İlaç (NSAİİ) Kullanan Hastalarda oluşan Gastroduodenal Lezyonların Önlenmesinde Misoprostolün Yeri. Atatürk Üniversitesi Tıp Dergisi 1997,29 (2):453-455.
5-N.Okçu, A. öz, m.d. onuk, e.akarsu, b. tekin, h.z. tonbul, h.kaya. Kronik Aktif Hepatit İle Dekopanse Karaciğer Parankim Yetmezliğinde Plazma Fibronektin Düzeyleri ve Karaciğerin Fonksiyon Durumu İle İlişkisi. Türk J. Gastroenterol 1995;27(4): 422-426.
6-N.Okçu, tahir buran,m.d. onuk,a. yılmaz, e.akarsu, g. akçay. Erzurum ve Çevresinde Duodenum Ülserli Hastalarda Helicobacter Pylori Prevelansı. Türk J. Gastroenterol 1995;27(4): 447-450.
7-N.Okçu, b.s. uyanık, e. akarsu, e. bakan, z. tonbul. Mide ve Kolorektal Kanserlerinde Karbonhidrat Antijenleri (CA-19-9, CA-125), Karsinoembriyonik Antijen (CEA) ve Alkalen Fosfatazın Önemi. Türk J. Gastroenterol 1995;6:467-471.
8-N. Okçu, m.d. onuk, e. akarsu, h. doğan, c. gündoğdu. Bölgemizdeki Hepatoselüler Karsinomlu Hastalarda Major Risk Faktörleri. Gastroenteroloji 1994;5(2):154-157
9-N.Okçu, m.d. onuk, e. akarsu, h. doğan, c.gündoğdu, tahir buran. Erzurum Bölgesinde Gastrik Karsinom Sıklığı, Endoskopik ce Histolojik Özellikler. Gastroenteroloji 1994;5(2):263-267.
10-N. Okçu, m.d. onuk, tahir buran, e. akarsu, m.a. çiftçioğlu. Erzurum İli Çevresinde Nonspesifik Gastritli Olgularda Helicobacter Pylori Sıklığı. Gastroenteroloji 1994;5(2):211-213.
11-N.Okçu, m.d. onuk, ö. ünal, e. akarsu, l. incesu, k. akgöz. Karın İçi Kitle Lezyonlarında Ultrason Rehberliğinde Yapılan İnce İğne Aspirasyon Biyopsisinin Tanı Değeri. Gastroenteroloji 1993;4(1):166-68.
12-N.O.kçu, m.d. onuk, m. polat, a. yılmaz, m. gündoğdu, m. paç. Budd-Chiari Sendromu (2 Olgu). Türk J Gastroenterhepatol 1993; 4(1):77-80.
13-N.Okçu, h. koçak, m.d. onuk, m. gündoğdu, e. bakan, a. yılmaz, a. başoğlu, a. ateş, f.a. paç. The Effect of Atrial Pressure Changes and Cardiac Nerves on Plasma Atrial Natriüretic Peptide (ANP) Levels. Vascular Surgery 1993; 27(2): 128-132
15-N.Okçu, m.d. onuk, a.yılmaz, m. gündoğdu, t. buran. Omeprozol ve Ranitidinin Peptik Ülser İyileşmesine Etkileri. Doğa-Tr.J. of Medical Sciences 1992;16:657-658.
16-N. Okçu, m.r. yiğitoğlu, b. adam, e. bakan. Konjestif Kalp Yetersizliği Olan Hastalarda Digıxin’in Plazma Atrial Natriüretik Peptik Düzeyine Etkisi. S.Ü. Tıp Fak. Dergisi 1991;7(2):243-247..
17-N.Okçu, a. yılmaz. Üst Gastrointestinal Sistem Kanamalarında Histamin H2 -Reseptör Antagonistlerinin Etkisi. Endoskopi Dergisi 1991;2(4):17-23.
18-N.Okçu, E. bakan, b. adam, a. yılmaz, m.r. yiğitoğlu. Kronik Hepatit ve Karaciğer Sirozlu Hastalarda Seks Hormanları ve Seks Hormon Bağlayıcı Globülin Seviyeleri (Editöre Mektup). Doğa-Tr. J. Of Medical Sciences 1991;15:1-2.
19-N.Okcu Ömer Yılmaz.Helıcobacter pylorı and related gastroıntestınal system dıseases Turkiye Klinikleri JMed Sci. 2013;33(3):806-13
20-Nihat Okçu , Ömer yılmaz, hakan dursun, gülçin polat. Dispeptik semptomlarla beslenme alışkanlıkları, endoskopik ve histolojik bulgular arasındaki ilişki (Eurasian J Med 2006; 38: 13-17)
21-Mehmet Bilici,1Nihat Okcu,1Kerim Cayır,1Ibrahim Pirim,2Salim B. Tekin,1andCemal Gundogdu3 - Distribuion of HLA Tissue Groups in Patients with Gastric Cancer Eurasian J Med. 2010 Apr; 42(1): 9.11.
22-Nihat Okcu,Abdulhalim Bak,Mehmet Sari,Mehmet Arslan,Sait Kapicioglu :The fibroblast proliferation,relationship of hepatocyte growth factor (HGF) and interferon-A2A Gastroenterology April 2000Volume 118,Issue 4, Part 2, PageA1404
23-Kubra Kaynar,Sait Kapicioglu,Mehmet Sarı,Nihat Okcu,Abdulhalim Baki. The effect of fish oil on stress ulcer prophylaxis GastroenterologyVolume 118, Issue 4, Part 2, PageA1255
Mehr lesenDr. Vladimir Yutkin ist ein hochqualifizierter Arzt am Hadassah Medical Center mit über 20 Jahren Erfahrung in der Diagnose und Behandlung urologischer Krebserkrankungen und Leiter der Abteilung für urologische Onkologie. Er schloss 1996 sein Studium an der Hebräischen Universität Jerusalem ab und spricht Englisch, Hebräisch und Russisch.
Mehr lesenLizenzierter Radioonkologe mit 8 Jahren medizinischer Ausbildung, einschließlich Grundstudium an der Medizinischen Fakultät der Marmara-Universität (2004-2011) und Spezialisierung auf Radioonkologie an der Medizinischen Fakultät der Marmara-Universität (2012-2016). Frühere Ausbildung an der Sixteen Numbered Shirvan School (Aserbaidschan) High School (1998-2004).
Mehr lesenArztbesuch | preis auf anfrage |
Chemotherapie bei Lungenkrebs | $1500 - $3700 |
Chemotherapie bei Bauchspeicheldrüsenkrebs | $1500 - $4500 |
Zungenkrebsoperation | $19000 |
Dr. Raj ist ein sehr erfahrener chirurgischer Onkologe mit 19 Jahren Erfahrung und über 50.000 durchgeführten Krebsoperationen. Er ist an zahlreichen klinischen Studien beteiligt und hat viele internationale und nationale Veröffentlichungen zu seinem Verdienst. Er ist spezialisiert auf Brust- und Thorax-Chirurgie-Onkologie und Professor für DNB Superspecialty Surgical Oncology and Breast Surgery an der Maharashtra University of Health Sciences. Sein Glaube ist, „den Jahren Leben hinzuzufügen“ und die Lebensqualität zu verbessern, nicht nur dem Leben Jahre hinzuzufügen.
Mehr lesenArztbesuch | preis auf anfrage |
Zungenkrebsoperation | $5900 - $8000 |
Chemotherapie bei Lungenkrebs | $1100 - $1250 |
Whipple-Operation | $8000 - $10000 |
Prof. M.D. Yusuf Serdar Sakin was born in Nevşehir in 1978. After completing his primary and secondary education in Ankara, he graduated from the Faculty of Medicine at Gülhane Military Medical Academy in 2002.
Following his graduation, he served in Gole/Ardahan for two years. He started his internal medicine training at the Department of Internal Medicine, Gülhane Faculty of Medicine.
After completing his training, he worked as an internal medicine specialist in Ankara. A year later, he began additional training in the Department of Gastroenterology at Gülhane Faculty of Medicine and completed his training in 2014.
After graduation, Yusuf Serdar Sakin continued to work in the same department. He also received advanced endoscopy and Motility training at AMC Center in the Netherlands in 2017.
After obtaining the title of Associate Professor in 2017, he became a Professor in 2023.
He currently provides medical services to patients at Koru Ankara Hospital. His areas of medical interest include:
-Endoscopic retrograde cholangiopancreatography (ERCP)
-Push enteroscopy
-Endoscopic mucosal resection
-High-resolution manometry
-pH/pH-impedance metry analysis
-Advanced endoscopic procedures (stenting, dilation, etc.)
-Gastrointestinal motility disorders
-Gastroesophageal reflux disease
-Inflammatory bowel diseases
-Advanced endoscopic procedures and pancreatitis.
Dr. Mouhamed Mounier Alwaw ist ein medizinischer Gastroenterologe mit mehr als 12 Jahren Erfahrung, der sich auf die Behandlung von Erkrankungen der Gallen- und Bauchspeicheldrüse, die Früherkennung von Dickdarmkrebs, die Blutstillung bei inneren Blutungen und die Behandlung von Fettleibigkeit durch einen Magenballon spezialisiert hat. Er hat MBBS-, MD- und Postgraduierten-Qualifikationen aus Syrien und Paris und ist versiert in Arabisch, Französisch und Englisch. Er hat umfangreiche internationale Veröffentlichungen, Essays und Präsentationen sowie verschiedene Forschungsprogramme zur Verringerung von Post-ERCP-Komplikationen und Zöliakie und Darmkrebs.
Mehr lesenDr. Alrawi ist ein hochqualifizierter und erfahrener, vom Vorstand zertifizierter chirurgischer Onkologe mit Fachkenntnissen in den Bereichen oberer Gastrointestinaltrakt, Kopf-Hals-Onkologie, minimalinvasive Onkologie, Brust-, kolorektale und beheizte Chemoperfusionsonkologie. Er hatte Positionen in tertiären Krebszentren inne und ist derzeit Direktor der Onkologiedienste im VPS-Krankenhaussystem in den VAE und MENA. Er ist auch in der onkologischen Forschung tätig.
Mehr lesenSpezialist für medizinische Onkologie mit Expertise in Lungen-, Brust-, Darm-, Magen-, Leber-, Nieren-, Bauchspeicheldrüsen-, Magen-, Prostata- und Gebärmutterkrebs. Erfahrung in Chemotherapie, Immuntherapie, Phytotherapie, Ozontherapie, hyperthermischer Chemotherapie, GIS-Krebs sowie gynäkologischem und Urogenitalkrebs. Mitglied der Turkish Oncology Group, Medical Oncology Association, Turkish Cancer Research and Warfare Association, European Society of Medical Oncology, European Society of Gynecologic Oncology und International Association for the Study of Lung Cancer.
Mehr lesen